GENERAL7 Sept 2026
Innovative ecosystem will make India attractive: Judith Love & Amitabh Dube
Novartis is changing its India strategy. It will focus on innovation, research and development, and clinical trials here. The company is moving away from traditional generics. It also wants a stronger regulatory ecosystem. This shift matters because it shows global confidence in India as an innovation hub. For business owners, an improved regulatory setup may open doors in healthcare and related fields. Watch how this develops.
Key Statutory Highlights
- Novartis is focusing on innovation, research and development, and clinical trials in India.
- Novartis is moving away from its traditional generics business.
- The company wants a stronger regulatory ecosystem in India.
Actionable Advice for Taxpayers / Founders:Keep a close watch on policy shifts in India's innovation and regulatory space, especially if you operate in healthcare or allied sectors.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: